AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Entera Bio Elects New Board Member and Approves Revised Compensation Terms at Annual Meeting
ByAinvest
Sunday, Jul 20, 2025 3:11 am ET1min read
Entera Bio elected Haya Taitel to its Board of Directors at its annual meeting, approved revised executive compensation, and ratified Kesselman & Kesselman as auditors. The election of a new board member is expected to positively impact the company's governance and financial oversight. Analysts rate ENTX as a Buy with a $10.00 price target.
Entera Bio Ltd. (NASDAQ: ENTX) held its 2025 Annual Meeting of Shareholders on Wednesday, where shareholders voted on several key proposals. The meeting saw the election of Haya Taitel to the Board of Directors for a three-year term, with 17,288,920 votes in favor, 3,069,140 against, 137,907 abstentions, and 6,197,026 broker non-votes [1].Additionally, shareholders ratified and approved revised compensation terms and a one-time grant of compensation for Chief Executive Officer and Director Miranda Toledano, with 19,524,783 votes for, 428,993 against, 542,191 abstentions, and 6,197,026 broker non-votes. Similar compensation proposals were approved for Chief of Research & Development Dr. Gregory Burshtein and Chief Financial Officer Dana Yaacov-Garbeli. Shareholders also ratified the company’s amended and restated compensation policy for directors and officers, and on an advisory, non-binding basis, compensation of the company’s named executive officers was approved [1].
Furthermore, shareholders approved the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the company’s independent auditors for the fiscal year ending December 31, 2025. The vote was 26,617,578 in favor, 59,966 against, and 15,449 abstentions [1].
The election of Haya Taitel to the Board of Directors is expected to positively impact the company's governance and financial oversight. Analysts rate ENTX as a Buy with a $10.00 price target.
References:
[1] https://www.investing.com/news/sec-filings/entera-bio-shareholders-approve-board-election-and-compensation-proposals-93CH-4142570
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet